Definition: Venous thromboembolism (VTE) is a blood clot that forms in a vein. NHLBI says it includes deep vein thrombosis (DVT), a clot usually in the lower leg, thigh or pelvis, and pulmonary embolism (PE), when a clot breaks loose and travels to the lungs. Up to 600,000 VTE events happen in the US each year.
NHLBI says risk is highest after major surgery, major injury, or during infection and inflammation, and that not moving after surgery or on long trips raises it. Swelling, redness and pain are signs of DVT; a PE can cause sudden chest pain and shortness of breath. The NCI adds that medicines containing hormones are among the causes of PE.
| Label | What it reports |
|---|---|
| Climara (WHI, estrogen alone) | DVT 23 vs 15 per 10,000 women-years on placebo |
| Climara (WHI, estrogen plus progestin) | Blood clots 35 vs 17; pulmonary embolism 18 vs 8 per 10,000 women-years |
| Evista (MORE trial) | About 1 in 100 women over an average 2.6 years; hazard ratio 2.4, highest in the first months |
Evista has a boxed warning for VTE. Its label says it is stopped at least 72 hours before and during long immobilization. Estrogen labels say estrogen is stopped right away if a clot is suspected, and, if feasible, 4 to 6 weeks before surgery linked to clots.
Several labels tie clot risk to surgery and long periods without moving. A log that shows your current hormone or SERM doses makes it easy to tell a surgeon what you take and since when.
Read more on Dose Track: Blood clots on TRT · Estrogen patch vs pill blood clot risk · Evista side effects · Climara side effects